<ul id="qe0qg"></ul> 
Our company continues to increase investment in R&D, focusing on oncology, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases and other main therapeutic areas, and is committed to improving human health through continuous innovation. To date, Our company has successfully marketed 7 innovative drugs.
The only globally-approved EPO mimetic peptide
XINYUE, licensed from Viela Bio, is a targeted CD19 B-cell depleting antibody for adult patients with AQP4-IgG+ NMOSD. In 2022, Inebilizumab was approved for marketing and included in the NRDL (2022 version).
Ameile is the first innovative third-generation EGFR-TKI drug wholly developed in China to treat NSCLC. It has been included in the Guidelines of Chinese Society of Clinical Oncology 2022 and renewed in the NRDL (2022 version).
Hengmu is the novel Tenofovir prodrug self-developed by the Group and the first oral dose medicine indicated for the treatment of hepatitis B virus (HBV) infection wholly developed in China.
Hansoh Xinfu is the second-generation Bcr-Abl TKI used as the first-line treatment of chronic myelogenous leukemia. It was renewed in the NRDL (2022 version).
Fulaimei is the first long-acting GLP-1 innovative drug wholly developed in China using the Group’s proprietary PEGylation technology. Fulaimei was renewed in the NRDL (2022 version).
Mailingda is the first self-developed innovative drug of the Group and the latest generation of nitroimidazole-class drug indicated for treatment of pelvic inflammatory disease in women. It is also included in the NRDL.
